Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein–Enriched Serum in Rheumatoid Arthritis

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2099-2105

  Ormseth, Michelle J ^a   Yancey, Patricia G ^a   Solus, Joseph F ^a   Louis Bridges, S ^b   Curtis, Jeffrey R ^b   Linton, MacRae F ^a   Fazio, Sergio ^c   Davies, Sean S ^a   Roberts, L Jackson ^a   Vickers, Kasey C ^a   Kon, Valentina ^a   Michael Stein, C ^a   Bingham, Clifton O ^d   Cofield, Stacey S ^d   Furie, Richard ^d   Gregersen, Peter K ^d   Genovese, Mark C ^d   Robinson, William H ^d   Levesque, Marc C ^d   Moreland, Larry W ^d   Nigrovic, Peter A ^d   Shadick, Nancy A ^d   O'Dell, James R ^d   Thiele, Geoffrey M ^d   St Clair, E William ^d   Striebich, Christopher C ^d   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; METHOTREXATE; TOCILIZUMAB;

ADULT; ARTICLE; DAS28; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLUOROMETRY; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84983507459     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39675     Document Type: Article

References (28)

1. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
2. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045–53.
3. Khera AV, Cuchel M, de la Llera-Moya M, Rodriques A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127–35.
4. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541–9.
5. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009;60:2870–9.
6. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012;71:1157–62.
7. Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the Treatment of Early Rheumatoid Arthritis trial. Arthritis Rheum 2013;65:1430–8.
8. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 2013;229:174–81.
9. Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2012;8:13–21.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
12. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012;60:2372–9.
13. Zanotti I, Favari E, Bernini F. Cellular cholesterol efflux pathways: impact on intracellular lipid trafficking and methodological considerations. Curr Pharm Biotechnol 2012;13:292–302.
14. De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30:796–801.
15. Robinet P, Wang Z, Hazen SL, Smith JD. A simple and sensitive enzymatic method for cholesterol quantification in macrophages and foam cells. J Lipid Res 2010;51:3364–9.
16. Zhou H, Shiu SW, Wong Y, Tan KC. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2009;6:238–43.
17. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712–9.
18. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 2015;3:507–13.
19. Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2014;73:609–15.
20. Ormseth MJ, Yancey P, Yamamoto S, Oeser AM, Gebretsadik T, Shintani A, et al. Cholesterol efflux capacity of HDL and coronary atherosclerosis in rheumatoid arthritis [abstract]. Arthritis Rheumatol 2014;66 Suppl:S634.
21. Ormseth MJ, Stein CM. High-density lipoprotein function in rheumatoid arthritis. Curr Opin Lipidol 2016;27:67–75.
22. Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015;4:e001588.
23. Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015;67:1155–64.
24. Hirao M, Yamasaki N, Oze H, Ebina K, Nampei A, Kawato Y, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int 2012;32:4041–5.
25. Rho YH, Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:1473–80.
26. Vivekanandan-Giri A, Slocum JL, Byun J, Tang C, Sands RL, Gillespie BW, et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis 2013;72:1725–31.
27. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383–93.
28. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696–705.